A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)

Start Date10 Apr 2026

Sponsor / Collaborator

Almirall SA

CTIS2024-519811-32-00

/ Not yet recruitingPhase 4

An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Start Date01 Apr 2026

Sponsor / Collaborator-

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Jan 2026

Sponsor / Collaborator

The University of California, San Francisco

100 Clinical Results associated with Lebrikizumab

100 Translational Medicine associated with Lebrikizumab

100 Patents (Medical) associated with Lebrikizumab

247

Literatures (Medical) associated with Lebrikizumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

Author: Yang, Xuefan ; Ruan, Dandan ; Li, Sitong ; Chen, Xiang ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

02 Mar 2026·Dermatitis

Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review.

Review

Author: Mehta, Apoorva ; Guttman-Yassky, Emma ; O'Hagan, Ross ; Lamb, Angela J ; Levine, Jasmine

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impairs quality of life. In recent years, treatment has advanced from broad immunosuppressants to targeted biologics and small-molecule therapies that modulate type 2 inflammation and itch signaling. Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are now FDA-approved biologics with demonstrated efficacy and favorable long-term safety, while oral Janus kinase inhibitors (JAKis) such as abrocitinib, upadacitinib, and baricitinib often provide rapid disease control but carry black-box warnings. Comparative trials highlight faster itch relief with JAKis but durable disease control and safety advantages with biologics. The expanding treatment landscape necessitates individualized therapy selection. Key clinical considerations include patient age, pregnancy status, infection, malignancy, or thromboembolic risk, comorbid conditions, and history of adverse effects. Equally important are patient-centered preferences such as dosing frequency, route of administration, storage logistics, and willingness to self-inject. Access and affordability also influence care, with many manufacturers offering copay support and patient assistance programs. Future directions emphasize head-to-head comparative studies, biomarker development for precision treatment, and equitable access to advanced therapies. This narrative review synthesizes current evidence on biologics and JAKis in AD, outlining efficacy, safety, and practical decision-making factors to guide dermatologists in aligning therapies with both clinical context and patient priorities.

01 Mar 2026·JOURNAL OF DERMATOLOGY

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long‐Term Treatment With Dupilumab: A Single‐Center Retrospective Study

Letter

Author: Chijiwa, Chika ; Okada, Yoshiki ; Tada, Yayoi ; Suzuki, Shoya ; Hiura, Azusa ; Kamata, Masahiro ; Tomura, Yayoi ; Hayashi, Kotaro ; Watanabe, Ayu ; Tanaka, Takamitsu

187

News (Medical) associated with Lebrikizumab

08 Apr 2026
·www.biospace.com

/C O R R E C T I O N -- American Academy of Dermatology/

In the news release, American Academy of Dermatology Issues First-Ever Pediatric Atopic Dermatitis Guidelines, Highlighting Prevention Strategies and Effective Treatments, issued 07-Apr-2026 by American Academy of Dermatology over PR Newswire, we are advised by the company that the 5th bullet in the list was modified to read "ruxolitinib cream" and a 6th bullet was added for "Topical aryl hydrocarbon receptor (AhR) agonists". The complete, corrected release follows: American Academy of Dermatology Issues First-Ever Pediatric Atopic Dermatitis Guidelines, Highlighting Prevention Strategies and Effective Treatments New evidence-based guidelines establish insufficient evidence or no benefit to dietary or environmental interventions ROSEMONT, Ill. , April 8, 2026 /PRNewswire/ -- For the first time in its history, the American Academy of Dermatology (AAD) has published guidelines of care for both the prevention and management of atopic dermatitis (commonly known as eczema) in pediatric patients. While pediatric and adult eczema share similarities, these guidelines recognize the unique safety, dosing, and patient-caregiver-clinician interactions of individuals under the age of 18. The most common pediatric skin disease, eczema affects up to 25% of children worldwide. It is a long-lasting inflammatory skin disease often marked by itchy skin, dry patches, rashes, and rough bumps. "Eczema is extremely common in children, though it doesn't always look or behave the same way it does in adults," said AAD President and board-certified dermatologist Murad Alam, MD, FAAD . "Because eczema can decrease the quality of life of children and their families, we need dedicated guidelines just for children to ensure their best care." The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD) , will guide dermatologists in deciding the best possible prevention and treatment options for pediatric patients. The guidelines were developed by a working group of 14 experts, including 11 board-certified dermatologists and one pediatric allergist. Prevention Because eczema is so common and can significantly affect a child's health, there is strong interest in identifying ways to help prevent it. However, current research shows that supplemental therapies like special diets or skipping baths aren't proven to prevent eczema. Moisturizers were the only treatment to receive a conditional recommendation for use to reduce the occurrence of eczema in children aged 6 months to 3 years. Conditional recommendations reflect an intervention whose benefits are closely balanced with risks and burdens. These recommendations apply to most patients, but the most appropriate action may differ depending on the patient and presentation. The guidelines find insufficient evidence or no benefit to dietary or environmental interventions, including early food introduction, human milk consumption, probiotic or vitamin D supplementation, water softening, and dust mite avoidance. Treatment There are more treatments for eczema than ever before, though standard treatments like regular moisturizing remain effective in managing eczema in children. The guidelines provide 26 evidence-based recommendations for topical therapies (prescription and non-prescription), phototherapy, and systemic therapies based on the treatment's reduction of eczema symptoms and itch severity, inclusive of the below. Strong recommendations reflect treatments in which benefits clearly outweigh the risks and burdens. These recommendations apply to most children with eczema in most circumstances. Strong recommendations were made for the use of the following: Moisturizers to reduce the severity of patients' dry, itchy skin. Topical calcineurin inhibitors (pimecrolimus 1% cream and tacrolimus 0.03% or 0.1% ointment) to manage patients' flares when their dry, itchy skin worsens and as intermittent maintenance therapy. Topical corticosteroids (steroid creams), considered a first-line treatment in most cases due to affordability and accessibility, to manage patients' flares and as maintenance therapy. Phosphodiesterate-4 inhibitors (crisaborole ointment and roflumilast cream) to reduce patients' itchiness and decrease the frequency of flares. When used proactively, roflumilast can keep skin clearer more consistently. Topical JAK inhibitors (ruxolitinib cream) to decrease the severity of the dry, itchy skin in patients with mild to moderate eczema. Topical aryl hydrocarbon receptor (AhR) agonists (tapinarof cream) to reduce inflammation, improve skin barrier function, and decrease the severity of dry, itchy skin in patients with mild, moderate and severe eczema. Monoclonal antibodies (dupilumab, tralokinumab, and lebrikizumab) to decrease the severity of eczema symptoms, reduce flares and improve itching in patients with moderate to severe eczema. JAK inhibitors (upadacitinib, abrocitinib, and baricitnib) to decrease the severity of eczema symptoms and improve itching in patients with moderate to severe eczema. Conditional recommendations were made for the use of treatments inclusive of the following: Bathing for treatment and maintenance for pediatric patients, followed by a moisturizer as standard care. Wet wrap therapy , under the guidance of a healthcare professional skilled in eczema management, are typically encouraged for patients during eczema flares. Phototherapy (light therapy) at a dermatologist's office can be used to treat patients with severe cases of eczema involving many body sites. Strong recommendations were made against systemic corticosteroids, which should be reserved exclusively for patients with sudden, severe flares and as short-term bridge therapy. Conditional recommendations were made against the use of topical antimicrobials and PUVA phototherapy for children with eczema. "These guidelines were developed to educate and empower patients, caregivers, and the medical community so children with eczema receive the best care possible. Early, proactive intervention allows improvement in symptoms and quality of life for patients and their families," said board-certified dermatologist Dawn Davis, MD, FAAD , co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "Since 2014, the landscape for eczema care has been transformed by the approval of new therapies for adults. Our goal was to review how these advancements relate to the pediatric population so children also receive optimal, individualized care." "Many children's eczema cases can be improved with a treatment plan made specially just for their needs, and starting treatment early can help keep the problem from getting worse," said Dr. Alam. "Please partner with a board-certified dermatologist to get expert care for your child's eczema." To find a board-certified dermatologist in your area, visit aad.org/findaderm. Resources Childhood Eczema About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org . Follow @AADskin on Facebook , TikTok , Pinterest , and YouTube , and @AADskin1 on Instagram . View original content to download multimedia: SOURCE American Academy of Dermatology

07 Apr 2026
·www.prnewswire.com

American Academy of Dermatology Issues First-Ever Pediatric Atopic Dermatitis Guidelines, Highlighting Prevention Strategies and Effective Treatments

New evidence-based guidelines establish insufficient evidence or no benefit to dietary or environmental interventions ROSEMONT, Ill., April 7, 2026 /PRNewswire/ -- For the first time in its history, the American Academy of Dermatology (AAD) has published guidelines of care for both the prevention and management of atopic dermatitis (commonly known as eczema) in pediatric patients. While pediatric and adult eczema share similarities, these guidelines recognize the unique safety, dosing, and patient-caregiver-clinician interactions of individuals under the age of 18. The most common pediatric skin disease, eczema affects up to 25% of children worldwide. It is a long-lasting inflammatory skin disease often marked by itchy skin, dry patches, rashes, and rough bumps. "Eczema is extremely common in children, though it doesn't always look or behave the same way it does in adults," said AAD President and board-certified dermatologist Murad Alam, MD, FAAD. "Because eczema can decrease the quality of life of children and their families, we need dedicated guidelines just for children to ensure their best care." The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric patients. The guidelines were developed by a working group of 14 experts, including 11 board-certified dermatologists and one pediatric allergist. Prevention Because eczema is so common and can significantly affect a child's health, there is strong interest in identifying ways to help prevent it. However, current research shows that supplemental therapies like special diets or skipping baths aren't proven to prevent eczema. Moisturizers were the only treatment to receive a conditional recommendation for use to reduce the occurrence of eczema in children aged 6 months to 3 years. Conditional recommendations reflect an intervention whose benefits are closely balanced with risks and burdens. These recommendations apply to most patients, but the most appropriate action may differ depending on the patient and presentation. The guidelines find insufficient evidence or no benefit to dietary or environmental interventions, including early food introduction, human milk consumption, probiotic or vitamin D supplementation, water softening, and dust mite avoidance. Treatment There are more treatments for eczema than ever before, though standard treatments like regular moisturizing remain effective in managing eczema in children. The guidelines provide 26 evidence-based recommendations for topical therapies (prescription and non-prescription), phototherapy, and systemic therapies based on the treatment's reduction of eczema symptoms and itch severity, inclusive of the below. Strong recommendations reflect treatments in which benefits clearly outweigh the risks and burdens. These recommendations apply to most children with eczema in most circumstances. Strong recommendations were made for the use of the following: Moisturizers to reduce the severity of patients' dry, itchy skin. Topical calcineurin inhibitors (pimecrolimus 1% cream and tacrolimus 0.03% or 0.1% ointment) to manage patients' flares when their dry, itchy skin worsens and as intermittent maintenance therapy. Topical corticosteroids (steroid creams), considered a first-line treatment in most cases due to affordability and accessibility, to manage patients' flares and as maintenance therapy. Phosphodiesterate-4 inhibitors (crisaborole ointment and roflumilast cream) to reduce patients' itchiness and decrease the frequency of flares. When used proactively, roflumilast can keep skin clearer more consistently. Topical JAK inhibitors (ruxolitinib cream and tapinarof cream) to decrease the severity of the dry, itchy skin in patients with mild to moderate eczema. Monoclonal antibodies (dupilumab, tralokinumab, and lebrikizumab) to decrease the severity of eczema symptoms, reduce flares and improve itching in patients with moderate to severe eczema. JAK inhibitors (upadacitinib, abrocitinib, and baricitnib) to decrease the severity of eczema symptoms and improve itching in patients with moderate to severe eczema. Conditional recommendations were made for the use of treatments inclusive of the following: Bathing for treatment and maintenance for pediatric patients, followed by a moisturizer as standard care. Wet wrap therapy, under the guidance of a healthcare professional skilled in eczema management, are typically encouraged for patients during eczema flares. Phototherapy (light therapy) at a dermatologist's office can be used to treat patients with severe cases of eczema involving many body sites. Strong recommendations were made against systemic corticosteroids, which should be reserved exclusively for patients with sudden, severe flares and as short-term bridge therapy. Conditional recommendations were made against the use of topical antimicrobials and PUVA phototherapy for children with eczema. "These guidelines were developed to educate and empower patients, caregivers, and the medical community so children with eczema receive the best care possible. Early, proactive intervention allows improvement in symptoms and quality of life for patients and their families," said board-certified dermatologist Dawn Davis, MD, FAAD, co-chair of the AAD's Atopic Dermatitis Guideline Workgroup. "Since 2014, the landscape for eczema care has been transformed by the approval of new therapies for adults. Our goal was to review how these advancements relate to the pediatric population so children also receive optimal, individualized care." "Many children's eczema cases can be improved with a treatment plan made specially just for their needs, and starting treatment early can help keep the problem from getting worse," said Dr. Alam. "Please partner with a board-certified dermatologist to get expert care for your child's eczema." To find a board-certified dermatologist in your area, visit aad.org/findaderm. Resources Childhood Eczema About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest, and YouTube, and @AADskin1 on Instagram. SOURCE American Academy of Dermatology 21% more press release views with Request a Demo

31 Mar 2026
·www.prnewswire.com

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78% experienced significant itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients 80% of patients achieved durable results without the need for topical corticosteroids March 27, 2026 -- New long-term data show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver.1 "These data underscore our unwavering commitment to expanding what people with moderate-to-severe atopic dermatitis can achieve with treatment," said Adrienne Brown, executive vice president and president, Lilly Immunology. "For too long the focus has been around symptom management and many patients struggle to achieve consistent disease control despite cycling through topical treatments. EBGLYSS is helping transform this treatment paradigm—allowing people the opportunity to reimagine life without the frequent interruptions caused by flares or topicals applied 2-3 times per day." EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity and slow dissociation rate.2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.5,6 In the ADlong study, the majority of patients achieved a high bar of near-complete skin clearance and significant itch relief with up to four years of continuous EBGLYSS treatment. Most patients (77%) were on EBGLYSS monotherapy, and 80% achieved results without topical corticosteroids. In addition, 80% achieved these outcomes with EBGLYSS monthly maintenance dosing during the study. The safety of EBGLYSS in the first year of the ADlong study was consistent with the known profile in patients with moderate-to-severe atopic dermatitis, regardless of dose frequency, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation. Reported treatment-related adverse events in the study included conjunctivitis (6.9%) and injection-site reactions (0.6%). The ADlong study is ongoing and will continue for an additional year of treatment. These results reinforce previously reported long-term results for EBGLYSS for patients with moderate-to-severe atopic dermatitis. In addition, a post-hoc analysis presented at Maui Derm Hawaii 2026 on EASI-75 stable responders showed less than one flare per patient per year with EBGLYSS monthly maintenance dosing used as monotherapy.7 "There is still an unmet need for people with moderate-to-severe atopic dermatitis who frequently experience unpredictable flares and are in need of treatment options that go beyond just symptomatic relief and address the underlying inflammation driving skin symptoms and persistent itch," said Emma Guttman-Yassky, M.D., Ph.D., The Waldman Professor and Health System Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York. "These four-year findings reinforce that EBGLYSS has the potential to deliver durable disease control, helping patients flare less with or without topicals." Lilly continues to raise the standard of care in dermatology and boldly invest in the next wave of immunology innovation, which includes big bets on next-generation modalities, the targeted expansion of small molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsA and TOGETHER-PsO trials investigating the concomitant use of ixekizumab and an incretin-based therapy to treat adults with psoriatic disease and obesity or overweight with at least one additional weight-related comorbid condition. Lilly's investigational therapies include DC-853, a novel oral IL-17 inhibitor being studied for psoriasis, and eltrekibart, a novel monoclonal antibody that targets neutrophil-driven inflammation and is being assessed in hidradenitis suppurativa. Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe. ADlong (NCT05916365) open-label extension study is evaluating the long-term safety and efficacy of EBGLYSS 250 mg dosed every four weeks (Q4W) in patients with moderate-to-severe atopic dermatitis for a total of 108 weeks. Adult and adolescent (ages 12–17, weighing ≥40 kg) patients from select countries in Europe who completed the 100-week ADjoin extension study, including patients who completed the ADore trial (52 weeks), the ADhere trial (16 weeks), and Week 16 responders who completed the ADvocate 1 and 2 trials (52 weeks), were eligible to enroll in ADlong. Patients (N=174) in this analysis receive open-label EBGLYSS 250 mg Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose). The approved maintenance dose of EBGLYSS is 250 mg once monthly, after taking EBGLYSS every two weeks for the four-month initial dosing phase (or later once achieving adequate clinical response).8 Intermittent use of topical rescue medications and short-term systemic treatments was allowed.1 If response was below EASI-50, Q2W could be used and thereafter Q4W could be resumed. EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate.3,4,8 EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of eczema, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13.8 The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating over 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin), adolescent open-label (ADore) and pediatric (ADorable 1 and 2) studies. EBGLYSS is also being studied in allergic rhinitis and chronic rhinosinusitis with nasal polyps. EBGLYSS was approved in the U.S., Japan and Canada in 2024 and in the European Union in 2023. EBGLYSS is a first-line biologic treatment with the option of monotherapy that offers once-monthly maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies.8 EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is a single monthly injection (250 mg every four weeks) which can be used with or without topical corticosteroids.8 Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans. We have expanded Medicaid coverage and are pursuing similarly broad Medicare coverage as part of Lilly's health equity and affordability initiative. Through Lilly Support Services, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients. Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. 1 Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial. American Academy of Dermatology Annual Meeting. March 2026 2 Simpson EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017 3 Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7 4 Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.024 5 Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954 6 Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018 7 Merola J, et al. Patients with Atopic Dermatitis with a Stable Response to Lebrikizumab Flare Less in a Long-Term Study: A Post-hoc Analysis of the ADjoin Study. Maui Derm Hawaii. January 2026 8 EBGLYSS. Prescribing Information. Lilly USA, LLC. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

100 Deals associated with Lebrikizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09633	Lebrikizumab	-	DB11914

R&D Status

Approved

10 top approved records.
Login
to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	European Union	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Iceland	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Liechtenstein	Almirall SA	16 Nov 2023
Dermatitis, Atopic	Norway	Almirall SA	16 Nov 2023

Developing

10 top R&D records.
Login
to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nummular eczema	Phase 3	Bulgaria	Almirall SA	10 Apr 2026
Nummular eczema	Phase 3	Germany	Almirall SA	10 Apr 2026
Nummular eczema	Phase 3	Italy	Almirall SA	10 Apr 2026
Nummular eczema	Phase 3	Poland	Almirall SA	10 Apr 2026
Nummular eczema	Phase 3	Spain	Almirall SA	10 Apr 2026
Chronic rhinosinusitis with nasal polyps	Phase 3	United States	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	China	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Japan	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Argentina	Eli Lilly & Co.	29 Apr 2024
Chronic rhinosinusitis with nasal polyps	Phase 3	Belgium	Eli Lilly & Co.	29 Apr 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05559359 (ADorable-1, Biospace) Manual	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	363	Lebrikizumab+Topical corticosteroids	wffxdgjxey(msntxxkfot) = aosqvkpxnn mvhhlfhfwc (ocpoienrzn ) Met View more	Positive	16 Mar 2026
				Placebo+Topical corticosteroids	wffxdgjxey(msntxxkfot) = xtofwijiet mvhhlfhfwc (ocpoienrzn ) Met View more
NCT04392154 (ADjoin, Literature \| NEWS) Manual	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	103	lebrikizumab Q8W	xiozkptcrj(zwgdjodqdu) = vcipbsrlgx nrudqdroxr (vtfwuokohi, 48.3 - 75.8) View more	Positive	10 Nov 2025
				lebrikizumab Q4W	xiozkptcrj(zwgdjodqdu) = eqngofrohy nrudqdroxr (vtfwuokohi, 60.9 - 85.1) View more
NCT04146363 \| NCT04178967 \| NCT04392154 (ADvocate1, Pubmed \| Clin Exp Dermatol)	Phase 3	Dermatitis, Atopic	-	Lebrikizumab every 4 weeks	ilfkudghsb(lynagnmkrd) = tdgdqebxsm nhesnoxvxg (vkuihndzob ) View more	Positive	08 Nov 2025
				Lebrikizumab every 2 weeks	ilfkudghsb(lynagnmkrd) = lcvbhpatzu nhesnoxvxg (vkuihndzob ) View more
NCT06243198 (CTgov)	Phase 1	-	24	Lebrikizumab (250 mg Lebrikizumab)	homyksmdhc = shtuckeaid pgnuvzodds (fxfqdemdaf, vqpgnwfnwu - nhbehzzegv) View more	-	12 Sep 2025
				Lebrikizumab (500 mg Lebrikizumab)	homyksmdhc = plsadwuksk pgnuvzodds (fxfqdemdaf, ilcsddgecg - ywdmlehjyb) View more
NCT05372419 (ADmirable, Pubmed \| Am J Clin Dermatol)	Phase 3	Dermatitis, Atopic	90	Lebrikizumab 250 mg (Fitzpatrick skin phototype IV-VI + Non-White race)	ehtvhqhtoh(kolicqwmgk) = qdkcisekgo tothvkxmdn (sobrajdjio ) View more	Positive	01 Sep 2025
NCT04392154 (ADjoin, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	1,153	Lebrikizumab (Open-Label Extension Addendum: Lebrikizumab Q4W)	jxiupamvit(xmemzjrfom) = lshykjetlk usmlladigu (dhtztyovhw, ckojryftji - hzzcyaawuk) View more	-	03 Aug 2025
				Lebrikizumab (Open-Label Extension Addendum: Lebrikizumab Q8W)	jxiupamvit(xmemzjrfom) = uflzwnvmnp usmlladigu (dhtztyovhw, pbjrwgndin - wvqyxjoelv) View more
NCT04392154 (ADjoin, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Moderate Atopic Dermatitis Maintenance Interleukin-13	-	Lebrikizumab 250 mg Q2W	zsagzignnr(begdrbuluk) = During ADjoin, adverse events were reported by 62.2% of patients from ADvocate1&2 and ADhere who received lebrikizumab Q2W or Q4W, with the majority being mild (31.5%) or moderate (27.0%) in severity, and 2.2% leading to discontinuation due to adverse event cmfspiesbd (xtvekcavrz )	Positive	01 Aug 2025
				Lebrikizumab 250 mg Q4W
NCT06444165 (CTgov)	Phase 3	Dermatitis, Atopic	55	Lebrikizumab Pen	ynsnrcbqlm = vtefspijfc itsrmqfbml (ftglesrcoh, vgfizjtwhp - gsbxljqnez) View more	-	29 Jul 2025
NEWS Manual	Phase 3	Dermatitis, Atopic	90	Ebglyss	lqpkkvnvxv(lrmldlwexj) = ltnsmnacuk fnemqbdtbo (qnrlhepsdl ) View more	Positive	22 Jul 2025
NCT05372419 (ADmirable, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	90	Lebrikizumab (Lebrikizumab 250 mg Q2W)	caiqcqmvrc = rrbnqphnao dxjdmbsiiy (uxqevxzeht, eqriddxmek - kqeceqctkt) View more	-	11 Jun 2025
				Lebrikizumab (Lebrikizumab 250 mg Q2W to Lebrikizumab 250 mg Q2W)	ohjoxcbtjs = uchhhifstl ikdnilmkur (fjdejmsbmv, capoejnbqx - qvlweprzay) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

view full example data

Deal

Boost your decision using our deal data.

login

view full example data

Core Patent

Boost your research with our Core Patent data.

login

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

login

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

login

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

view full example data

AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free

Lebrikizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation